Arnon R, Van Regenmortel M H
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.
FASEB J. 1992 Nov;6(14):3265-74. doi: 10.1096/fasebj.6.14.1385242.
This manuscript describes the design of new vaccines based on synthetic peptides. To this end, we first analyze the structural basis of antigenic reactivity and specificity and the various types of epitopes that form the mosaics of macromolecular antigens, as well as the regulatory mechanisms involved in immune recognition. A distinction is made between sequential or continuous epitopes, and discontinuous or conformational ones, which are the majority of epitopes in globular proteins. In this context it is of particular interest to identify epitopes reacting with B cells and T cells, respectively, or with cytotoxic T cells, in association with the major histocompatibility cell-surface antigens, and the role of these interactions in protective immunity. Identification of such epitopes in proteins of viral, bacterial, or parasitic organisms led to the synthesis of peptides, which when used in conjunction with appropriate carriers and/or adjuvants induced neutralizing antibodies. Particular examples are described, including: bacterial epitopes and mainly those of toxins of diphtheria, cholera, and shigella, leading not only to neutralizing antibodies but also to protective immunity against the deleterious effects of the respective toxins; parasite epitopes, such as those leading to anti-malaria vaccine, based on either the sporozoite or the merozoite stage antigens; viral epitopes leading to protective immunity, with special emphasis on influenza virus where induction of CTL is crucial; and finally, synthetic peptide vaccines against HIV, which should lead to broad specificity protective immunity while avoiding the risks of a vaccine based on the infectious agent. The rapid recent progress in this field, as described in this review, increases the prospect of constructing successful synthetic peptide vaccines in the not too distant future.
本手稿描述了基于合成肽的新型疫苗的设计。为此,我们首先分析了抗原反应性和特异性的结构基础、构成大分子抗原镶嵌体的各种表位类型,以及免疫识别所涉及的调节机制。区分了序列或连续表位与不连续或构象表位,后者是球状蛋白中大多数表位的类型。在这种情况下,特别令人感兴趣的是分别鉴定与B细胞和T细胞或与细胞毒性T细胞反应的表位,这些表位与主要组织相容性细胞表面抗原相关,以及这些相互作用在保护性免疫中的作用。在病毒、细菌或寄生虫生物体的蛋白质中鉴定出此类表位后,就可以合成肽,当与适当的载体和/或佐剂一起使用时,这些肽可诱导产生中和抗体。文中描述了一些具体例子,包括:细菌表位,主要是白喉、霍乱和志贺氏菌毒素的表位,这些表位不仅能诱导产生中和抗体,还能提供针对相应毒素有害作用的保护性免疫;寄生虫表位,例如基于子孢子或裂殖子阶段抗原的抗疟疾疫苗的表位;能产生保护性免疫的病毒表位,特别强调了诱导细胞毒性T淋巴细胞对流感病毒至关重要;最后是针对艾滋病毒的合成肽疫苗,这种疫苗应能产生广泛特异性的保护性免疫,同时避免基于感染原的疫苗所带来的风险。如本综述所述,该领域最近的快速进展增加了在不久的将来构建成功的合成肽疫苗的前景。